Chronic Obstructive Pulmonary Disease
Jun 30, 2026
Zymeworks Announces Acquisition of Theravance Biopharma; Ipsen to Acquire Kartos Therapeutics; Viridian Therapeutics Wins U.S. FDA Approval for Lumvoa; Replimune Reaches FDA Milestone with RP1 BLA Resubmission Acceptance; Epicrispr Announces Encouraging Clinical Data for EPI-321 in FSHD
Zymeworks Signs Definitive Agreement to Acquire Theravance Biopharma Zymeworks Inc. has signed a definitive agreement to acquire Theravance Biopharma, Inc., marking a strategic step in expanding its commercial portfolio. The acquisition will bring YUPELRI®, the first and only once-daily nebulized long-acting mus...
Read More...
Mar 31, 2026
Tanabe Pharma Shares Encouraging Phase 3 Data for Dersimelagon in Rare Photodermatoses; Biogen’s Litifilimab Demonstrates Significant Skin Disease Reduction in Phase 2 CLE Trial; Merck’s WINREVAIR Shows Promising Phase 2 Results in CpcPH-HFpEF Population; AstraZeneca’s Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III COPD Trials; Amgen’s REPATHA Shows Strong Cardiovascular Risk Reduction in High-Risk Patients
Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for Dersimelagon in EPP and XLP Tanabe Pharma Corporation has announced detailed findings from the Phase 3 INSPIRE trial evaluating investigational oral dersimelagon in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The ...
Read More...
Sep 24, 2025
Smart Inhalers: Redefining Respiratory Care with Technology and Data
The smart inhalers market has been rapidly evolving as digital health and connected medical devices gain traction worldwide. With increasing adoption of telemedicine, remote monitoring, and personalized healthcare, smart inhalers are emerging as a transformative solution for both patients and healthcare providers. ...
Read More...
Sep 12, 2025
DUPIXENT’s Launch Brings Next Chapter of Biologics in COPD
COPD management has progressively centered on bronchodilator-based regimens, with Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-agonists (LABAs) forming the therapeutic core. Dual LAMA/LABA therapy is standard for moderate disease, while triple therapy with Inhaled Corticosteroids (ICS) is reserve...
Read More...
Dec 10, 2024
AbbVie Reveals Phase III TEMPO-2 Trial Positive Topline Results; FDA Accepts GSK’s NUCALA Submission in COPD; Novartis Boosts Huntington’s Disease Development Program with PTC518 In-Licensing; Chimerix to File for Accelerated FDA Approval of Dordaviprone for H3 K27M-Mutant Diffuse Glioma; MeiraGTx Receives FDA RMAT Designation for AAV2-hAQP1 in Grade 2/3 Radiation-Induced Xerostomia Treatment
AbbVie Unveils Positive Phase III TEMPO-2 Trial Findings for Tavapadon as Parkinson's Disease Monotherapy AbbVie announced favorable topline results from its pivotal Phase III TEMPO-2 trial, which assessed the investigational drug tavapadon as a flexible-dose monotherapy for early-stage Parkinson's disease. Tava...
Read More...
Oct 01, 2024
IntraBio’s AQNEURSA Niemann-Pick Disease Approval; FDA Approves Novel Schizophrenia Drug After 35 Years; Selpercatinib Gets FDA Nod for RET-Mutated MTC; DUPIXENT Receives First-Ever COPD Approval; Pfizer Withdraws OXBRYTA for Sickle Cell Disease from Global Market
IntraBio's AQNEURSA Receives Historic FDA Approval for Niemann-Pick Disease Type C Treatment IntraBio Inc. has received approval from the FDA for AQNEURSA (levacetylleucine), marking a significant milestone in the treatment of neurological manifestations of Niemann-Pick disease type C in both adults and pe...
Read More...
Sep 10, 2024
Biogen’s SPINRAZA Phase II/III Trial Results; Travere’s FILSPARI FDA Approval; GSK’s NUCALA Succeeds in COPD Trial; Summit’s NSCLC Win Over KEYTRUDA Raises Caution; FDA Lifts Hold on RZ358 for Congenital Hyperinsulinism
Biogen's Higher SPINRAZA Dose Shows Improved Efficacy in Phase II/III Trial A trial studying a higher dose of Biogen’s spinal muscular atrophy drug SPINRAZA (nusinersen) has met the primary endpoint in a cohort of infants with SMA. The Phase II/III DEVOTE study, which included 145 patients across various ages an...
Read More...
Jul 09, 2024
Lilly’s Morphic Acquisition; IDEAYA’s IDE397 Positive Phase II Trial Result; XPOVIO (selinexor) Approval in China; Roche to Reintroduce Susvimo in the US; Dupixent EU Approval
Lilly Strengthens IBD Treatment Portfolio with Morphic Acquisition Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for serious chronic diseases. Lilly will initiate a tender offer to acqu...
Read More...
Jul 02, 2024
Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR EU CHMP Recommendation; Verona Pharma’s Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval
Eisai Announces Solo Venture for Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate Eisai Co., Ltd. announced the termination of its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), previously known as MORAb-202, an ...
Read More...
Jan 24, 2024
Airway Management Devices: Charting the Evolving Market Trends and Key Innovations
Technological evolution has significantly transformed Airway Management Devices in recent years, ushering in a new era of efficiency, precision, and patient safety. Advances in materials, design, and manufacturing processes have led to the development of more sophisticated devices. Moreover, the incorporation of hi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
